达利珠单抗和OKT3预防肾移植术后急性排斥反应的比较  

Comparison of the efficacy of Simulect and OKT3 for prevention of acute renal allograft rejection

作　　者：方针强[1] 张艮甫[1] 黄赤兵[1] 范明齐[1] 

机构地区：[1]第三军医大学附属新桥医院泌尿外科,重庆400037

出　　处：《中华器官移植杂志》2004年第3期155-156,共2页Chinese Journal of Organ Transplantation

摘　　要：目的　比较达利珠单抗和OKT3预防肾移植术后早期急性排斥反应的效果。方法　肾移植受者在使用环孢素A(或他克莫司 )、霉酚酸酯及激素预防急性排斥反应的基础上加用达利珠单抗 (42例 )或OKT3(12 8例 ) ,观察 2个组肾移植术后 3个月内急性排斥反应发生率。结果　肾移植术后 3个月内 ,使用达利珠单抗者急性排斥反应发生率为 2 .4 % ,明显低于使用OKT3者的13.3% (P <0 .0 5 ) ,且前者无耐激素者 ,急性排斥反应的发生时间推迟 ,血肌酐恢复正常的时间也早于使用OKT3者。结论　达利珠单抗预防肾移植术后急性排斥反应的效果优于OKT3。Objective To compare the clinical efficacy of Simulect and OKT3 for prevention of acute renal allograft rejection. Methods A total of 170 first cadaveric kidney transplant recipients were randomized to receive Simulect (Simulect group, n=42) or OKT3 (OKT3 group, n=128) subject to triple immunosuppression therapy (CsA/FK506, Cellcept and prednisone). The incidence of acute rejection was observed in both groups.Results Simulect group had less frequent incidence of acute rejection ( 2.4 % versus 13.2 %, P< 0.05) during the first 3 months after renal transplantation compared to OKT3 group. The 3-month person/graft survival rate in Simulect group and OKT3 group was 100 % and 99.2 %, respectively, with the difference being not statistical.Conclusion Simulect is an ideal immunosuppressive agent which is more effective for prevention of acute renal transplant allograft rejection than OKT3.

关 键 词：达利珠单抗 OKT3 预防措施 肾移植术 急性排斥反应 单克隆 抗体 

分 类 号：R699.2[医药卫生—泌尿科学]